Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 164 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical Placebo Gel Clear all
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

NCT03578029
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
RGN-137, Placebo
Drug
Lead sponsor
Lenus Therapeutics, LLC
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 13, 2026, 3:55 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis

NCT02565732
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

NCT03826550
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo
Drug · Other
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
24
States / cities
Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of PG101 for Dry Eye Syndrome

NCT02078661
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
PG101
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 13, 2026, 3:55 PM EDT
Terminated Phase 2 Interventional Results available

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

NCT04570956
View directory record Official record
Conditions
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
Interventions
Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Evanston, Illinois • Rochester, Minnesota • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Beta Adrenergic Antagonist for the Healing of Chronic DFU

NCT03282981
View directory record Official record
Conditions
Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound
Interventions
Timolol, Non biologically active gel
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 13, 2026, 3:55 PM EDT
Not listed Phase 1 Interventional

Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution

NCT00260767
View directory record Official record
Conditions
HIV
Interventions
HEC placebo gel
Drug
Lead sponsor
Biosyn
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2005 · Synced Sep 13, 2026, 3:55 PM EDT
Not listed Phase 2 Interventional

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

NCT05735158
View directory record Official record
Conditions
Autosomal Recessive Ichthyosis
Interventions
KB105, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rancho Santa Margarita, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis

NCT01533480
View directory record Official record
Conditions
Keratoconjunctivitis Due to Adenovirus, Viral Shedding
Interventions
Zirgan, genteal gel
Drug
Lead sponsor
Lifelong Vision Foundation
Other
Eligibility
14 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

NCT03630939
View directory record Official record
Conditions
Psoriatic Plaque
Interventions
ESR-114, Placebo
Drug · Other
Lead sponsor
Escalier Biosciences B.V.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Santa Monica, California • Tampa, Florida • Fridley, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 2 Interventional Results available

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer

NCT02556632
View directory record Official record
Conditions
Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
Interventions
Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis, Placebo, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Gary Morrow
Other
Eligibility
21 Years and older · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Newark, Delaware • Decatur, Illinois • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 1Phase 2 Interventional

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

NCT04261387
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
LUT014 Gel, Placebo for LUT014 Gel
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Columbus, Georgia • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of UC-781 Vaginal Microbicide

NCT00132444
View directory record Official record
Conditions
HIV Infections
Interventions
topical vaginal application of UC-781 gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 13, 2026, 3:55 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

NCT05529134
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
PTW-002 10 mg/g gel, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

NCT00285207
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Interventions
placebo, A007
Drug
Lead sponsor
Tigris Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2010 · Synced Sep 13, 2026, 3:55 PM EDT
Terminated Phase 3 Interventional

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

NCT01830348
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination

NCT00821652
View directory record Official record
Conditions
Tumors
Interventions
NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo
Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04134273
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CLPG Topical Gel 1%, Clindamycin, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

NCT02580370
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 13, 2026, 3:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 13, 2026, 3:55 PM EDT
Terminated Not applicable Interventional

Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes

NCT00567528
View directory record Official record
Conditions
Soft Tissue Injury
Interventions
ibuprofen
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years to 19 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 13, 2026, 3:55 PM EDT